Vascular effects of newer Cardiovascular drugs: Focus on nebivolol and ACE-inhibitors

Journal of Cardiovascular Pharmacology

Volumn 38, Issue SUPPL. 3, 2002, Pages

  Luscher T F ^a   Spieker, L E ^a   Noll, G ^a   Cosentino, F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Endothelin; Free radicals; Hypertension; Nitric oxide

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ASCORBIC ACID; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; FOLIC ACID; LOSARTAN; NEBIVOLOL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RAMIPRILAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG MECHANISM; HEART INFARCTION; HUMAN; HYPERTENSION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; STROKE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0036135341     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200112003-00002     Document Type: Article

References (147)

1. Hyperlipidemia and atherosclerosis
2. The pathogenesis of atherosclerosis - An update
3. The pathogenesis of atherosclerosis: A perspective for the 1990s
4. Atherosclerosis - An inflammatory disease
5. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
6. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
7. Flow-induced release of endothelium-derived relaxing factor
8. Flow-mediated and reflex changes in large peripheral artery tone in humans
9. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
10. Biochemistry of nitric cxide and its redox-activated forms
11. Vascular endothelial cells synthesize nitric oxide from L-arginine
12. L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation
13. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man
14. Nitric oxide regulates basal systemic and pulmonary vascular reastance in healthy humans
15. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo
16. Role of basal and stimulated release of nitric oxide in the regulation of radial artery caliber in humans
17. Baroreceptor dysfunction induced by nitric oxide synthase inhibition in man
18. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids
19. Nitric oxide attenuates cardiac myocyte contraction
20. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
21. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
22. Phosphoramidon, a metalloproteinase inhibitor, suppresses the secretion of endothelin-1 from cultured endothelial cells by inhibiting a big endothelin-1 converting enzyme
23. Purification and characterization of endothelin-converting enzyme from rat lung
24. Purification and characterization of a phosphorarmdon-sensitive endothelin-converting enzyme in porcine aortic endothelium
25. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells
26. The human preproendothelin-1 gene. Complete nucleotide sequence and regulation of expression
27. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
28. Release of endothelin from the porcine aorta. Inhibition of endothelium-derived nitric oxide
29. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium
30. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells
31. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium
32. Acute pulmonary alveola r hypoxia increases lung and plasma endothelin-1 levels in conscious rats
33. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not
34. Production of endothelin by cultured porcine endothelial cells: Modulation by adrenaline
35. Cytokine-induced release of endothelin-1 from porcine renal epithelial cell line
36. Cytokine stimulated endothelin release from endothelial cells
37. Interleukin-2 enhances the release of endothelin-1 from the rat mesenteric artery
38. Cytokine and lipopolysaccharide stimulation of endothelin-1 release from human internal mammary artery and saphenous vein smooth-muscle cells
39. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries
40. Role of neutral endopeptidase in the metabolism of endothelin
41. Metabolism of endothelin-1 and big endothelin-1 by recombinant neutral endopeptidase EC.3.4.24.11
42. Endothelin is a potent mitogen for rat vascular smooth muscle cells
43. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
44. B receptors mediate vascular smooth muscle cell contraction
45. B receptors mediate contraction to endothelin-1 in human blood vessels
46. Cloning and expression of a cDNA encoding an endothelin receptor
47. Cloning and functional expression of a vascular smooth muscle endothelin 1 receptor
48. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men
49. Pulmonary clearance of lating endothelin-1 in dogs in vivo: Exclusive role of ETB receptors
50. Human pulmonary circulation is an important site for both clearance and production of endothelin-1
51. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells
52. Clearance of circulating endothelin-1 by ETB receptors in rats
53. Mobilization of intracellular calcium by endothelin in Swiss 3T3 cells
54. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation
55. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: Effects of calcium antagonists
56. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?
57. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
58. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease
59. Polar secretion of endothelin-1 by cultured endothelial cells
60. Radio-immunoassay of endothelin in human plasma
61. Contribution of endogenous generation of endothelin-1 to basal vascular tone
62. Identification of endothelin receptors in cultured cerebellar neurons
63. Identification of endothelin receptors in various regions of rat brain
64. Regional hemodynamic and baroreflex effects of endothelin in rats
65. G-nitro-L-arginine methyl ester
66. Different effects of low and high doses of endothelin on haemodynamics and hormones in the normotensive conscious dog
67. Cardiovascular and endocrine effects of endothelin-1 at pathophysiological and pharmacological plasma concentrations in conscious dogs
68. Central effects of endothelin on baroreflex of spontaneously hypertensive rats
69. Effects of centrally administered endothelin-3 on renal sympathetic nerve activity and renal blood flow in conscious rats
70. Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure
71. Modulatory effects of endothelin on baroreflex activation in the nucleus of the solitary tract
72. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers
73. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat
74. Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension?
75. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
76. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells
77. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis
78. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
79. Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat
80. L-Arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits
81. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries
82. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats
83. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins
84. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors
85. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats
86. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone
87. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension
88. 2 in angiotensin II-induced vascular hypertrophy
89. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats
90. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension
91. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: Role of blood pressure and endothelial function
92. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries
93. Effects of vasodilatory beta-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney
94. An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis
95. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor
96. Vasoconstriction in the rat kidney induced by endothelin-1 is blocked by PD 145065
97. Analysis of vasocontractile responses to endothelin-1 in rabbit retinal vessels using an ETA receptor antagonist and an ETB receptor agonist
98. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension
99. Structure and function of small arteries in salt-reduced hypertension: Effects of chronic endothelin-subtype-A-receptor blockade
100. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ET(A)-receptor antagonist
101. ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension
102. Effect of antihypertensive treatment and N-omega-nitro-L-argmme methyl ester on cardiovascular structure in deoxycomcosterone acetate-salt hypertensive rats
103. Effect of chronic treatment with two different ET(A) selective endothelin receptor antagonists on blood pressure and small artery structure of deoxycorticosterone acetate (DOCA)-salt hypertensive rats
104. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats
105. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
106. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
107. Nitric oxide activity in the atherosclerotic human coronary circulation
108. Clinical morbidities in subjects with doppler-evaluated endothelial dysfunction of coronary artery
109. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
110. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
111. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
112. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication
113. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
114. Cholesterol reduction rapidly improves endothelial function after acute coronaryl syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial
115. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
116. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
117. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND Study
118. Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients
119. Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients
120. Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients
121. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure
122. Structure and function of resistance arteries of hypertensive patients treated with a beta-blocker or a calcium channel antagonist
123. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients
124. Nifedipine enhances endothelium-dependent relaxation and inhibits contractions to endothelin-1 and phenylephrine in hypertension
125. Effect of captopril and enalapril on endothelial function in hypertensive patients
126. Effect of anti-hypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension
127. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia
128. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial
129. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension
130. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease
131. Long-term ascorbic acid administration reverses endothelial vasomotor dysfunction in patients with coronary artery disease
132. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus
133. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia
134. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers
135. Treatment of hypertension with ascorbic acid
136. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
137. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans
138. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo
139. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction
140. Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure
141. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism
142. Nitric oxide mediated venodilator effects of nebivolol
143. Nebivolol: Comparison of the effects of DL-nebivolol, D-nebivolol, L-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure
144. Sympathetic outflow to muscles during treatment of hypertension with metoprolol
145. The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension